Premium
Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma
Author(s) -
Chan Anthony W H,
Kumada Takshi,
Toyoda Hidenori,
Tada Toshifumi,
Chong Charing C N,
Mo Frankie K F,
Yeo Winnie,
Johnson Philip J,
Lai Paul B S,
Chan Anthony T C,
To KaFai,
Chan Stephen L
Publication year - 2016
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13291
Subject(s) - medicine , hepatocellular carcinoma , liver cancer , gastroenterology , bilirubin , cohort , stage (stratigraphy) , paleontology , biology
Background and Aims The albumin–bilirubin (ALBI) grade is a recently reported, simpler, more objective, and evidence‐based alternative to the Child–Pugh (CP) score for hepatocellular carcinoma (HCC). We aimed to study whether ALBI grade could substitute for CP score in Barcelona Clinic Liver Cancer (BCLC) for HCC. Methods An international multicentre cohort ( n = 3696) was accrued to compare the prognostic performance of the CP‐based and ALBI‐based BCLC system, in terms of homogeneity, discriminatory ability, and monotonicity of gradients that were numerically reflected by homogeneity likelihood, linear trend chi‐squares, and c‐indices, respectively. Results The ALBI grade performed as well as CP score when integrated into the BCLC staging system in terms of predicting clinical outcome of HCC regardless of regions, etiology, and treatment options. CP‐based and ALBI‐based BCLC systems were highly concordant with weighted kappa value of 0.917. All restaged patients showed significantly different clinical outcomes compared with their original stage classification. In particular, ALBI‐based BCLC upstaged 83 (2.2%) patients from lower CP‐based BC LC stages to ALBI‐based BCLC stage D, whose median overall survival was only 3 months. Conclusions The overall prognostic performance of ALBI‐based and CP‐based BCLC systems was similar. It also potentially allows more precise patient selection for clinical trials on systemic agents.